Otsuka and Ionis report positive data in Phase III FUSION trial of ulefnersen

Otsuka Pharmaceutical Development & Commercialization, Otsuka Pharmaceutical, and Ionis Pharmaceuticals have reported encouraging top-line data from the Phase III FUSION trial. Ulefnersen showed a statistically significant improvement against placebo on a combined measure assessing functional impairment. FUS-ALS is a rare, rapidly progressing ALS form, with no currently approved therapies directly addressing its genetic cause. Credit: Faizal Ramli / Shutterstock.com. Otsuka Pharmaceutical Development & Commercialization (OPDC), Otsuka Pharmaceutical, and Ionis Pharmaceuticals have reported encouraging top-line data from the Phase III FUSION trial. The trial is to assess an investigational therapy, ulefnersen, to treat people with a genetic form of amyotrophic lateral…

Source: Clinical Trials Arena